The majority of people who develop low-level viral load on dolutegravir resuppress viral load without needing to change treatment, a large Nigerian study has found, confirming observations regarding the frequency of viral load resuppression from the ADVANCE study of first-line antiretroviral treatment in South Africa.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.